GWPH - GW Pharmaceuticals foresees Q4 revenue above consensus

GW Pharmaceuticals ([[GWPH]] +2.6%) expects Q4 net product sales to be ~$148M vs. consensus of $141.16M and ~$526M for FY2020 vs. consensus of $520.99M.Total Epidiolex net product sales expected to be ~$144M for the quarter comprising of $129M in the US and $15M ex-US.  and ~$510M for fiscal year.Cash and cash equivalents at December 31, 2020 were ~$486M.Pivotal US clinical program for nabiximols in MS spasticity is underway. Initial data expected in 2021. “Epidiolex sales increased by over 70% in 2020 despite the challenges of COVID-19, reflecting the positive impact this medicine has on patients as well as the performance of our commercial team. We remain encouraged by our patients’ experience on this product, as demonstrated by high persistence and refill rates. This, combined with our expansion of payer coverage and the recently approved Tuberous Sclerosis Complex indication, leads us to expect continued strong growth in 2021 in both the US and

For further details see:

GW Pharmaceuticals foresees Q4 revenue above consensus